Real world study of safety and efficacy of lorlatinib as second line and beyond in < em > ALK < /em > -rearranged advanced non-small cell lung cancer patients in India - a multicentre chart review study (ROSELAND)
CONCLUSION: Lorlatinib was highly efficacious in terms of overall response rate, median PFS and median OS in this small real-world cohort of advanced ALK+ve NSCLC with a manageable safety profile.PMID:38439810 | PMC:PMC10911676 | DOI:10.3332/ecancer.2024.1667
Source: Ecancermedicalscience - Category: Cancer & Oncology Authors: Bivas Biswas Nikhil S Ghadyalpatil Shekar Patil Amol Patel Sandip Ganguly Anvesh Rathore Bhupesh Guleria Cpalli Firdouse Tarannum Joydeep Ghosh Mary Sravani Kondapally Ravi Thippeswamy Shashidhara Haragadde Poppa Reddy Somnath Roy Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | India Health | Lung Cancer | Lymphoma | Neurology | Non-Small Cell Lung Cancer | Study | Toxicology